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106 Poster Session-IIlong-term survival in pts with hematologic malignancies and com-
promised organ function (COF); however, pts with advanced disease
do poorly with RIC alone (Giralt, Biol. Blood Marrow Transplant,
13:884, 2007). In an attempt to improve the anti-tumor efficacy of
RIC, while maintaining a low-toxicity profile, we added TMLI to
FLU/MEL. We hypothesize that Flu/Mel with 1200 cGY of
TMLI delivered usingTomotherapyHi-Art system is safe, tolerable,
and may improve outcome in pts with COF and advanced hemato-
logical malignancies.
Patients and Methods: Pts, $50 years of age or COF with
advanced disease status defned as high-risk remission and marrow
blasts #10%, were eligible. The RIC consisted of FLU 25 mg/m2/
d x 5 days, MEL 140 mg/m2 for one day, and TMLI delivered at
150 cGy/fraction in 8 fractions over 4 days.
Results: There were 16 evaluable pts (median age: 50.8 yr range
24.3–65.7 yr). The diagnoses were: AML (n 5 10), ALL (n 5 3),
NHL (n 5 2), multiple myeloma (n 5 1),. At the time of HSCT 9
patients (56%) had advanced disease: 1st or 2nd relapse (n5 3), induc-
tion failure (n5 5) and progressive disease (n5 1). Seven pts (44%)
were in complete remission. Mobilized peripheral blood stem cells
from HLA-identical siblings (n 5 7) or matched unrelated donor
(n 5 9) were used in all cases. Transplant-related toxicities by day
130 included: nausea grade 2 (n5 4) grade 3 (n5 12), emesis grade
2 (n5 6) and grade 3 (n5 4), mucositis grade 2 (n5 2) and grade 3
(n 5 14) and fatigue grade 2 (n 5 6) grade 3 (n 5 4). Myeloid and
platelet engraftment occurred at a median of 15 (range: 10–19
days) and 16 (range:10–19 days) days post transplant, respectively.
Acute GvHD grade II-IV occurred in 38.5% of patients (grade II
(31%) and grade III in 7.5%) and extensive chronic GVHD in 3
patients (19%). Five patients expired; 2 of relapsed disease, 1 with
a secondary malignancy, and 2 of transplant related mortality. At
a median of 12 month overall survival (OS) and disease-free survival
(DFS) are 81% (95% CI, 51%–93%), and 59% (95% CI,
23%–82%), respectively.
Conclusion: The addition of TMLI at a dose to RIC with FLU/
MEL appears to be tolerable and safe. The low rate of relapse and
improved OS and DFS compared to historical data are promising.
A study is ongoing to further assess efficacy in pts with hematological
malignancies who are not eligible for RIC due to disease burden.
292
CYCLOSPORINE, MYCOPHENOLATE MOFETIL AND METHOTREXATE AS
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Introduction:Nonmyeloablative (NM) hematopoietic cell trans-
plantation (HCT) has extended the potential curative treatment
option of allografting to patients in whom it was previously contrain-
dicated due to advanced age or comorbidity. Graft-versus-host
disease (GvHD), however, remains one of the major impediments
to long term remission. Recently, our group has introduced a modi-
fied post grafting immunosuppression by adding methotrexate
(MTX) onto the standard mycophenolate mofetil (MMF)/cyclo-
sporin (CsP) for NMHCT recipients., with significant reduction in
severe GvHD and non relapse mortality (NRM), thereby conferring
favorable survival in patients receiving NMHCT. The current study
is initiated to assess the feasibility and efficacy of similar approach in
the setting of single institution with additional patient accrual.
Patients and Methods: Twenty-seven patients (median age, 47
years) with hematological diseases, who were poor candidates for
a conventional myeloablative transplantation, receiving NM condi-
tioning with fludarabine 90 mg/m2 and total body irradiation
(TBI) 200-cGy, followed by filgrastim-mobilized peripheral blood
stem cell transplant from HLA identical (n5 26), or matched unre-
lated (n 5 1) donors. Diagnosis include leukemia/MDS (n 5 17),
lymphoma (n 5 2), ALL (n 5 1), myeloma (n 5 5) and CML (n 5
2). All patients were given CSP, MMF and short course of MTX
as post-grafting immunosuppression.
Results: The median times to neutrophil (500/mL) and platelet
recovery (20,000/mL) were 20 and 13 days, respectively. Myelosup-
pression was moderate with neutrophil counts not declining below
500/mL in 5 (19%) patients, and with more than half of the patientsnot requiring any blood or platelet transfusion. Non-relapse mortal-
ity was lowwith no transplant related death occurring within the first
1 year. Overall, 11 (20%) patients had grade 2–4 acute GvHD, with
only 5 (9%) patients experiencing grade 3–4 acute GVHD. Acute
GVHD was diagnosed at median day 198 (range, days 133 to
1158). Extensive chronic GVHD was observed in 2 of 24 evaluable
patients (8.3%). Relapse-related death occurred in 6 (11%) patients.
At median follow-up of 40months (range, 20–57months), the 4-year
probability of overall and progression-free survival were 61% and
42%, respectively.
Conclusions: The addition of MTX onto the CSP and MMF as
post grafting immunosuppresion offers the possibility of further
optimization of GvHD control in patients receiving NMHCT,
with encouraging survival.
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AML andMDS are moderately sensitive to the graft-versus leuke-
mia effect, therefore making the preparative regimen dose intensity
an important part of the treatment plan. For patients older than
age 55, the optimal conditioning regimen prior to HSCT remains
to be determined. Because of the high rates of morbidity and mortal-
ity associated with HSCT in the elderly, many patients older than
50–55 years are excluded from treatment with myeloablative condi-
tioning regimens. Herein, we report promising findings using intra-
venous (IV) BuFlu myeloablative conditioning regimen in patients
older than age 54 years with AML or MDS.
Methods:A cohort of 74 patients age 55 years with AML (n5 60)
with high or intermediate risk cytogenetics or MDS (n 5 14) with
a high IPSS were transplanted in first complete remission (CR1) or
with disease beyond CR1. The preparative regimen consisted of
IV Flu 40 mg/m2 and IV Bu 130 mg/m2 given once daily over 3
hours on pre-transplant days -6 to -3. Graft-versus-host disease
(GVHD) prophylaxis was accomplished with use of Tacrolimus
and methotrexate.
Results: Median age was 58 years (range 55–66); 18 patients
(24%) were older than 59 years. Fifty-four percent of patients were
in complete remission (CR); 32% in first CR (CR1) and 22% in
second CR (CR2); 46% had active disease. Donors were HLA-
matched related (50%) and unrelated (50%). All patients engrafted.
Forty-one percent and 7% of the patients had grades II-IV and
III-IV acute GVHD, respectively. Chronic GVHD rate was 42%.
Median follow-up is 22 months (range 1–82 months). Two-year
overall survival (OS) was 70%, 48%, and 35% for patients trans-
planted in CR1, CR2, and with active disease, respectively. For
patients in CR1, CR2, and with active disease at time of HSCT,
actuarial 2-year event free survival (EFS) is 65%, 45%, and 30%, re-
spectively. Thirty-two percent of the patients have relapsed (n5 24).
Disease progression (n5 22), GVHD (n5 8), infection (n5 3), and
organ failure (n 5 3) were the primary causes of death. TRM and
survival are shown in Table.
Conclusion:Our results show lowTRM rates for selected patients
in the 6th and 7th decades of life with high-risk AML andMDS who
received BuFlu. Furthermore, long-term follow up indicates that
responses with this regimen are stable in a significant proportion of
patients. We conclude that age in itself should not be the primary
reason to exclude patients from receiving myeloablative transplants.Cumulative Incidence of Transplant-Related Mortality (TRM)
by Pre-Transplant Disease Status
TRM 30-Days 100-Days 1-yearAll patients None 4% 21%
All CR (n540) None 5% 18%
CR1 (n524) None 4% 15%
Persistent Disease (n534) None 3% 27%
